"Treatments in the Phase IIb clinical study of NTCELL® in Parkinson’s disease were completed at the end of April and we are now eagerly waiting for the results to be unblinded in November. The 130 weeks’ post-implant results of the Phase I/IIa clinical study were announced in June. The study continued to meet the primary endpoint of safety and patients continued to show a reversal of the progression of Parkinson's disease".
Net assets $7.5mill.
Roll on Movember
Ann: Preliminary Final Report and Financial Statements, page-3
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 4863067 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 950168 | 3 |
View Market Depth
| Last trade - 16.12pm 18/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |
Day chart unavailable